SANJIVANI PARANTERAL LIMITED
205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: 13th February, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Scrip Code: 531569

Sub: Outcome of Board Meeting held on Friday, 13th February, 2026

Dear Sir/Madam,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("the Listing Regulations"), we wish to inform you that, in their meeting held today i.e. 13th February, 2026 has inter-alia considered and approved the following:

1. Unaudited Financial Results along with Limited Review Report as submitted by the statutory auditor of the Company for the Third Quarter and Nine Months Ended 31st December, 2025.

Accordingly, the Unaudited Financial Results for Third Quarter and Nine Months Ended 31st December, 2025 along with Limited Review Report are attached herewith as **"Annexure I".**

The meeting of the Board commenced at 04:30 P.M. and concluded at 05:00 P.M.
Kindly take the above on record.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

RAVIKUMAR VENKATRAMALU BOGHAM
Digitally signed by RAVIKUMAR VENKATRAMALU BOGHAM
Date: 2026.02.13 17:05:11 +05'30'

Ravikumar Venkatramuloo Bogam
Company Secretary Cum Compliance Officer

SANJIVANI PARANTERAL LIMITED

REGD OFFICE : 205,P.N. KOTHARI INDL.ESTATE,L.B.S.MARG,BHANDUP (W), MUMBAI - 400 078
TEL NO. 022 20812600 Email ID: info@sanjivani.co.in
CIN: L24300MH1994PLC081752

STANDALONE UN-AUDITED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER'2025

Rs. In Lacs (Except earning per share)

SR. NO.	PARTICULARS	QUARTER ENDED ON			NINE MONTHS ENDED ON		PREVIOUS YEAR ENDEDN ON
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	(AUDITED)
1	**REVENUE FROM OPERATIONS**						
	a) REVENUE FROM OPERATIONS	2086.32	1549.73	1734.91	5425.27	5191.72	7009.86
	b) OTHER INCOME	29.05	16.39	31.18	49.03	78.67	121.35
	TOTAL REVENUE	**2115.37**	**1566.12**	**1766.09**	**5474.30**	**5270.39**	**7131.21**
2	**EXPENSES**						
	a) COST OF MATERIAL CONSUMED	1341.07	1066.01	1011.41	3547.57	2395.49	3356.30
	b) CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE	77.45	(32.44)	(18.49)	15.96	713.49	692.07
	c) EMPLOYEE BENEFITS EXPENSES	162.42	149.42	164.55	463.70	438.64	649.32
	d) FINANCE COSTS	20.86	4.96	19.39	47.73	39.02	59.27
	e) DEPRECIATION AND AMORTIZATION EXPENSES	18.68	16.85	15.90	51.89	43.70	62.09
	f) OTHER EXPENSES	146.03	142.16	322.42	549.37	870.16	1276.17
	TOTAL EXPENSES	**1766.51**	**1346.96**	**1515.18**	**4676.22**	**4500.50**	**6095.22**
3	**PROFIT/ (LOSS) BEFORE TAX (1-2)**	**348.86**	**219.16**	**250.91**	**798.08**	**769.89**	**1035.99**
4	**TAX EXPENSES**						
	- CURRENT	87.19	53.01	61.07	197.20	179.07	184.53
	- DEFERRED	0.00	2.30	0.00	2.30	0.00	41.28
5	**NET PROFIT / (LOSS) FOR THE PERIOD (9-10)**	**261.67**	**163.85**	**189.84**	**598.58**	**590.82**	**810.18**
6	OTHER COMPREHENSIVE INCOME (NET OF TAXES)	0.00	0.00	0.00	0.00	0.00	0.00
7	**TOTAL COMPREHENSIVE INCOME FOR THE PERIOD**	**261.67**	**163.85**	**189.84**	**598.58**	**590.82**	**810.18**
8	**COMPREHENSIVE INCOME FOR THE PERIOD ATTRIBUTABLE TO THE OWNERS OF THE PARENT**	**261.67**	**163.85**	**189.84**	**598.58**	**590.82**	**810.18**
9	**Paid-up Equity Share Capital, (Face Value RS.10/- Each)**	1228.43	1228.43	1168.43	1228.43	1168.43	1188.17
10	**EARNING PER SHARE (IN Rs.)**						
	a) Baisc Earnings (Loss) Per Share	2.13	1.33	1.62	4.87	5.06	6.89
	b) Diluted Earnings (Loss) Per Share	2.13	1.33	1.62	4.87	5.06	6.67

Financial Notes :

1. The above standalone financials results of the Company have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act,2013 read with relevant rules issued thereunder.

2. The above standalone Financial Results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 13th February' 2026

3. Previous Year's / Period's figures have been regrouped or reclassified wherever necessary.

4. The Statutory Auditors have carried out a 'Limited Review of the Company's results in terms of Clause 41 of the Listing Agreement with Stock Exchange.

5. Company has only one business segment of pharmaceutical in terms of the requirement as per IND AS 108 on "Operating Segment Reporting"

6 Despite an increase in net profit during the period under review, the Earnings Per Share (EPS) has marginally decreased due to the conversion of warrants into equity shares, resulting in an increase in the paid-up share capital. Consequently, the expanded equity base has led to dilution in EPS.

Key Operational Highlights :

1 Challenges and way forward

The Company has successfully overcome the challenges prevailing in the previous quarter and was able to clock higher revenues. The Compnay is now geared up to demonstrate a study peformance in the coming period.

2 Global Expansion – New Market Access

Sanjivani currently exports approximately 77% of its revenue across 20 countries spanning three continents. We have successfully completed stringent regulatory audits for three additional countries, paving the way to enter a newer geographies. These markets will contribute incremental revenue in the upcoming quarters, supported by our track record of quality, competitive pricing, and high repeat business from global clients.

3 IV Fluid Plant – (Pune) Forward Orders

Our new, advanced IV fluid manufacturing facility in Pune has started the commercial dispatches during period under review. The plant already holds a robust forward order book covering the next 90 days, with a healthy mix of domestic and export commitments. This facility is a key milestone in strengthening Sanjivani's presence in both institutional and private-label healthcare segments.

FOR SANJIVANI PARANTERAL LTD.

SANJIVANI PARANTERAL LIMITED

Place : Mumbai

Date : 13th February 2026

ASHWANI KHEMKA
MANAGING DIRECTOR
DIN: 00337118

R. B. Gohil & Co.
Chartered Accountants

Review Report to
The Board of Directors
Sanjivani Paranteral Ltd.

We have reviewed the accompanying statement of unaudited Standalone financial results of M/s Sanjivani Paranteral Ltd. for the quarter and nine months ended 31st December'2025 which are included in the accompanying 'Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2025 (the "Statement'). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the "Listing Regulations, 2015), which has been initialed by us for identification purpose. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors, which have been prepared in accordance with the recognition and measurement principals laid down in Indian Accounting Standard for Interim Financial Reporting, (IND-AS 34) prescribed under Section 133 of the Companies Act,2013 read with relevant rules issued there under and other accounting principles generally accosted in India. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements /results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the statement is not modified.

For R.B.Gohil & Co.
Chartered Accountants
FRN: 119360W

R.B. GOHIL & CO. M.No.104997 JAMNAGAR Chartered Accountants

Raghubha B Gohil
Partner
Membership No.104997
Date : 13th February 2026
UDIN : 26104997CDCRDC6789

SANJIVANI PARANTERAL LIMITED

REGD OFFICE : 205,P.N. KOTHARI INDL.ESTATE,L.B.S.MARG,BHANDUP (W), MUMBAI - 400 078
TEL NO. 022 20812600 Email ID: info@sanjivani.co.in
CIN: L24300MH1994PLC081752

CONSOLIDATED UN-AUDITED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER'2025

Rs. In Lacs (Except earning per share)

SR. NO.	PARTICULARS	QUARTER ENDED ON			NINE MONTHS ENDED ON		PREVIOUS YEAR ENDEDN ON
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	(AUDITED)
1	**REVENUE FROM OPERATIONS**						
	a) REVENUE FROM OPERATIONS	2206.29	1549.73	1734.91	5545.24	5191.72	7009.86
	b) OTHER INCOME	29.51	16.39	31.18	49.49	78.67	121.50
	TOTAL REVENUE	**2235.80**	**1566.12**	**1766.09**	**5594.73**	**5270.39**	**7131.36**
2	**EXPENSES**						
	a) COST OF MATERIAL CONSUMED	1401.91	1066.01	1011.41	3608.41	2395.49	3356.30
	b) CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE	71.46	(32.44)	(18.49)	9.97	713.49	692.07
	c) EMPLOYEE BENEFITS EXPENSES	175.60	149.42	164.55	476.88	438.64	649.32
	d) FINANCE COSTS	20.86	4.96	19.39	47.73	39.02	59.27
	e) DEPRECIATION AND AMORTIZATION EXPENSES	22.73	16.85	15.90	55.94	43.70	62.09
	f) OTHER EXPENSES	173.42	142.16	322.42	576.76	870.16	1277.07
	TOTAL EXPENSES	**1865.98**	**1346.96**	**1515.18**	**4775.69**	**4500.50**	**6096.12**
3	**PROFIT/ (LOSS) BEFORE TAX (1-2)**	**369.82**	**219.16**	**250.91**	**819.04**	**769.89**	**1035.24**
4	**TAX EXPENSES**						
	- CURRENT	92.19	53.01	61.07	202.20	179.07	184.53
	- DEFERRED	0.00	2.30	0.00	2.30	0.00	41.28
5	**NET PROFIT / (LOSS) FOR THE PERIOD (9-10)**	**277.63**	**163.85**	**189.84**	**614.54**	**590.82**	**809.43**
6	OTHER COMPREHENSIVE INCOME (NET OF TAXES)	0.00	0.00	0.00	0.00	0.00	0.00
7	**TOTAL COMPREHENSIVE INCOME FOR THE PERIOD**	**277.63**	**163.85**	**189.84**	**614.54**	**590.82**	**809.43**
8	**COMPREHENSIVE INCOME FOR THE PERIOD ATTRIBUTABLE TO :**						
	THE OWNERS OF THE PARENT	**271.24**	**163.85**	**189.84**	**608.15**	**590.82**	**809.72**
	NON - CONTROLLING INTEREST	**6.39**	**0.00**	**0.00**	**6.39**	**0.00**	**(0.29)**
9	**Paid-up Equity Share Capital, (Face Value RS.10/- Each)**	1228.43	1228.43	1168.43	1228.43	1168.43	1188.17
10	**EARNING PER SHARE (IN Rs.)**						
	a) Baisc Earnings (Loss) Per Share	2.21	1.33	1.62	5.00	5.06	6.89
	b) Diluted Earnings (Loss) Per Share	2.21	1.33	1.62	5.00	5.06	6.66

Financial Notes :

1. The above consolidated financials results of the Company have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act,2013 read with relevant rules issued thereunder.

2. The above consolidated Financial Results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 13th February' 2026

3. Previous Year's / Period's figures have been regrouped or reclassified wherever necessary.

4. The Statutory Auditors have carried out a 'Limited Review of the Company's results in terms of Clause 41 of the Listing Agreement with Stock Exchange.

5. Company has only one business segment of pharmaceutical in terms of the requirement as per IND AS 108 on "Operating Segment Reporting"

6 Despite an increase in net profit during the period under review, the Earnings Per Share (EPS) has marginally decreased due to the conversion of warrants into equity shares, resulting in an increase in the paid-up share capital. Consequently, the expanded equity base has led to dilution in EPS.

Key Operational Highlights :

1 Challenges and way forward

The Company has successfully overcome the challenges prevailing in the previous quarter and was able to clock higher revenues. The Compnay is now geared up to demonstrate a study peformance in the coming period.

2 Global Expansion – New Market Access

Sanjivani currently exports approximately 77% of its revenue across 20 countries spanning three continents. We have successfully completed stringent regulatory audits for three additional countries, paving the way to enter a newer geographies. These markets will contribute incremental revenue in the upcoming quarters, supported by our track record of quality, competitive pricing, and high repeat business from global clients.

3 IV Fluid Plant – (Pune) Forward Orders

Our new, advanced IV fluid manufacturing facility in Pune has started the commercial dispatches during period under review. The plant already holds a robust forward order book covering the next 90 days, with a healthy mix of domestic and export commitments. This facility is a key milestone in strengthening Sanjivani's presence in both institutional and private-label healthcare segments.

FOR SANJIVANI PARANTERAL LTD.

SANJIVANI PARANTERAL LIMITED

Place : Mumbai

Date : 13th February 2026

ASHWANI KHEMKA
MANAGING DIRECTOR
DIN: 00337118

R. B. Gohil & Co.
Chartered Accountants

Review Report to
The Board of Directors
Sanjivani Paranteral Ltd.

We have reviewed the accompanying statement of unaudited Consolidated financial results of M/s Sanjivani Paranteral Ltd. for the quarter and nine months ended 31st December'2025 which are included in the accompanying 'Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025 (the "Statement'). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the "Listing Regulations, 2015), which has been initialed by us for identification purpose. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors, which have been prepared in accordance with the recognition and measurement principals laid down in Indian Accounting Standard for Interim Financial Reporting, (IND-AS 34) prescribed under Section 133 of the Companies Act,2013 read with relevant rules issued there under and other accounting principles generally accosted in India. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements /results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The statement includes the results of the only subsidiary M/s SPL Infusion Pvt. Ltd. We did not review the interim financial information of this only subsidiary included in the unaudited consolidated financial results of the Parent.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the statement is not modified.

For R.B.Gohil & Co.
Chartered Accountants
FRN: 119360W

R. B. GOHIL & CO. M. No. 104997 JAMNAGAR Chartered Accountants

Raghubha B Gohil
Partner
Membership No.104997
Date : 13th February 2026
UDIN : 26104997CDCRDC1572